Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Eight-Week, Randomized, Double-Blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus.

Next Previous
Search
Trial Profile

An Eight-Week, Randomized, Double-Blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren (Primary) ; Ramipril
  • Indications Essential hypertension
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 06 Nov 2012 Planned number of patients (846) added as reported by European Clinical Trials Database.
    • 10 May 2011 New source from European Clinical Trials Database identified (EudraCT2004-001062-40) and integrated.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top